Clinical trial
Single Blind, Randomized, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Booster Immunization With Bivalent Vaccine Against Tetanus and Diphtheria CLODIVAC (IBSS Biomed S.A.) and Td-Impfstoff Mérieux (Sanofi Pasteur) in Healthy Adults.
NCT05480462 is registered in ClinicalTrials.gov with IBSS Biomed S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single Blind, Randomized, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Booster Immunization With Bivalent Vaccine Against Tetanus and Diphtheria CLODIVAC (IBSS Biomed S.A.) and Td-Impfstoff Mérieux (Sanofi Pasteur) in Healthy Adults.
- Lead sponsor
- IBSS Biomed S.A.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 12, 2022
- Completion date
- June 30, 2024
- Enrollment
- 200 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.